UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 25, 2012
|
PHARMACYCLICS, INC.
|
||
|
(Exact Name of Registrant as specified in Charter)
|
||
|
Delaware
|
000-26658
|
94-3148201
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
995 E. Arques Avenue, Sunnyvale, California
|
94085-4521
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
|
Registrant’s telephone number, including area code: (408) 774-0330
|
||
|
(Former Name or Former Address, if Changed Since Last Report.)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Joshua T. Brumm
On October 25, 2012, Pharmacyclics, Inc. (the “Company”) appointed Joshua T. Brumm, 34, its Executive Vice President of Finance as the Company’s Principal Financial Officer and Principal Accounting Officer.
For information with respect to Mr. Brumm’s business experience and compensation, please see the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 15, 2012.
Corporate Bonus Plan
On October 25, 2012, the Company adopted a 2013 corporate cash bonus plan applicable to all employees of the Company, including its named and other executive officers, other than the Company’s Principal Executive Officer. The amount to be paid pursuant to the corporate cash bonus plan to an employee is a percentage of such employee’s salary ranging from 10% to 50% as determined by their executive level and whether corporate, department and personal goals are met, with a portion to be paid for 2013 and a portion to be paid in future periods upon the satisfaction of specified goals.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
October 29, 2012
|
PHARMACYCLICS, INC.
|
|||
|
By:
|
/s/ Joshua T. Brumm
|
||
|
Name:
|
Joshua T. Brumm | ||
|
Title:
|
Executive Vice President, Finance | ||